These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 33655823)

  • 1. Natural Sourced Inhibitors of EGFR, PDGFR, FGFR and VEGFRMediated Signaling Pathways as Potential Anticancer Agents.
    Nandi S; Dey R; Samadder A; Saxena A; Saxena AK
    Curr Med Chem; 2022; 29(2):212-234. PubMed ID: 33655823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer.
    Taeger J; Moser C; Hellerbrand C; Mycielska ME; Glockzin G; Schlitt HJ; Geissler EK; Stoeltzing O; Lang SA
    Mol Cancer Ther; 2011 Nov; 10(11):2157-67. PubMed ID: 21885862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer?
    Capdevila J; Carrato A; Tabernero J; Grande E
    Crit Rev Oncol Hematol; 2014 Nov; 92(2):83-106. PubMed ID: 24924525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
    Thomson S; Petti F; Sujka-Kwok I; Epstein D; Haley JD
    Clin Exp Metastasis; 2008; 25(8):843-54. PubMed ID: 18696232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SOMCL-085, a novel multi-targeted FGFR inhibitor, displays potent anticancer activity in FGFR-addicted human cancer models.
    Jiang XF; Dai Y; Peng X; Shen YY; Su Y; Wei MM; Liu WR; Ding ZB; Zhang A; Shi YH; Ai J
    Acta Pharmacol Sin; 2018 Feb; 39(2):243-250. PubMed ID: 28905937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family.
    Brave SR; Ratcliffe K; Wilson Z; James NH; Ashton S; Wainwright A; Kendrew J; Dudley P; Broadbent N; Sproat G; Taylor S; Barnes C; Silva JC; Farnsworth CL; Hennequin L; Ogilvie DJ; Jürgensmeier JM; Shibuya M; Wedge SR; Barry ST
    Mol Cancer Ther; 2011 May; 10(5):861-73. PubMed ID: 21441409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intedanib, a triple kinase inhibitor of VEGFR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis.
    Antoniu SA; Kolb MR
    IDrugs; 2010 May; 13(5):332-45. PubMed ID: 20432191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors.
    Li Y; Tan C; Gao C; Zhang C; Luan X; Chen X; Liu H; Chen Y; Jiang Y
    Bioorg Med Chem; 2011 Aug; 19(15):4529-35. PubMed ID: 21724404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epoxyquinol B shows antiangiogenic and antitumor effects by inhibiting VEGFR2, EGFR, FGFR, and PDGFR.
    Kamiyama H; Kakeya H; Usui T; Nishikawa K; Shoji M; Hayashi Y; Osada H
    Oncol Res; 2008; 17(1):11-21. PubMed ID: 18488711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Molecular Targets of Anticancer Therapy - Current Status and Perspectives.
    Zajac M; Muszalska I; Jelinska A
    Curr Med Chem; 2016; 23(37):4176-4220. PubMed ID: 27528054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. To Investigate Growth Factor Receptor Targets and Generate Cancer Targeting Inhibitors.
    Basu D; Pal R; Sarkar M; Barma S; Halder S; Roy H; Nandi S; Samadder A
    Curr Top Med Chem; 2023; 23(30):2877-2972. PubMed ID: 38164722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From Tumor to Bone: Growth Factor Receptors as Key Players in Cancer Metastasis.
    Mohammad KS; Akhund SA
    Front Biosci (Landmark Ed); 2024 May; 29(5):184. PubMed ID: 38812320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiokinase inhibition of VEGFR-2, PDGFR and FGFR and cell growth inhibition in lung cancer: Design, synthesis, biological evaluation and molecular docking of novel azaheterocyclic coumarin derivatives.
    Ahmed EY; Elserwy WS; El-Mansy MF; Serry AM; Salem AM; Abdou AM; Abdelrahman BA; Elsayed KH; Abd Elaziz MR
    Bioorg Med Chem Lett; 2021 Sep; 48():128258. PubMed ID: 34246754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity.
    Holmström TH; Moilanen AM; Ikonen T; Björkman ML; Linnanen T; Wohlfahrt G; Karlsson S; Oksala R; Korjamo T; Samajdar S; Rajagopalan S; Chelur S; Narayanan K; Ramachandra RK; Mani J; Nair R; Gowda N; Anthony T; Dhodheri S; Mukherjee S; Ujjinamatada RK; Srinivas N; Ramachandra M; Kallio PJ
    Mol Cancer Ther; 2019 Jan; 18(1):28-38. PubMed ID: 30301864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
    Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
    Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural products as important tyrosine kinase inhibitors.
    Yin B; Fang DM; Zhou XL; Gao F
    Eur J Med Chem; 2019 Nov; 182():111664. PubMed ID: 31494475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance.
    Fischer T; Najjar A; Totzke F; Schächtele C; Sippl W; Ritter C; Hilgeroth A
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1-8. PubMed ID: 29098884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of lung tumor growth by targeting EGFR/VEGFR-Akt/NF-κB pathways with novel theanine derivatives.
    Zhang G; Ye X; Ji D; Zhang H; Sun F; Shang C; Zhang Y; Wu E; Wang F; Wu F; Tian H; Liu X; Chen L; Liu K; Wang Y; Liu H; Zhang W; Guan Y; Wang Q; Zhao X; Wan X
    Oncotarget; 2014 Sep; 5(18):8528-43. PubMed ID: 25138052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virtual screening of selective multitarget kinase inhibitors by combinatorial support vector machines.
    Ma XH; Wang R; Tan CY; Jiang YY; Lu T; Rao HB; Li XY; Go ML; Low BC; Chen YZ
    Mol Pharm; 2010 Oct; 7(5):1545-60. PubMed ID: 20712327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural Products Targeting EGFR Signaling Pathways as Potential Anticancer Drugs.
    Wang X; Xu L; Lao Y; Zhang H; Xu H
    Curr Protein Pept Sci; 2018 Feb; 19(4):380-388. PubMed ID: 28059040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.